Modifying the thermostability of inactivated influenza vaccines

Vaccine

Volumn 30, Issue 37, 2012, Pages 5506-5511

  Bliu, Alex ^a   Lemieux, Michele ^a   Li, Changgui ^b   Li, Xuguang ^a   Wang, Junzhi ^b   Farnsworth, Aaron ^a  

^a HEALTH CANADA   (Canada)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Influenza; Thermostability; Vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; IMMUNOGENICITY; PH; PRIORITY JOURNAL; THERMOSTABILITY; VIRUS ENTRY;

ANALYSIS OF VARIANCE; ANIMALS; BENZAMIDES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INDUSTRY; DRUG STABILITY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HYDROGEN-ION CONCENTRATION; HYDROQUINONES; INFLUENZA VACCINES; MADIN DARBY CANINE KIDNEY CELLS; ORTHOMYXOVIRIDAE; PIPERIDINES; VACCINES, INACTIVATED;

EID: 84864310550     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.051     Document Type: Article

References (32)

1. Nicholson K.G., Wood J.M., Zambon M. Influenza. Lancet 2003, 362:1733-1745.
2. Chan DM. In: Pandemic, W.n.a.t.s.o.i., editors. Geneva: WHO; 2009.
3. Robertson J.S., Nicolson C., Harvey R., Johnson R., Major D., Guilfoyle K., et al. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 2011, 29:1836-1843.
4. Ageing. D.o.H.a. Withdrawal of Panvax Junior. In: Administration, T.G., editors; 2010.
5. Canada, H. New Expiry Date for Unused Adjuvanted H1N1 Vaccine in Information Update, vol. 2010. Ottawa; 2010.
6. Health, M.D.o. Vaccine Recalls 2010.
7. Hardy S., Eichelberger M., Griffiths E., Weir J.P., Wood D., Alfonso C. Confronting the next pandemic-workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests 2011, Influenza Other Respi Viruses.
8. Farnsworth A., Cyr T.D., Li C., Wang J., Li X. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 2011, 29:1529-1533.
9. Hebert D.N., Foellmer B., Helenius A. Calnexin and calreticulin promote folding, delay oligomerization and suppress degradation of influenza hemagglutinin in microsomes. EMBO J 1996, 15:2961-2968.
10. Carr C.M., Chaudhry C., Kim P.S. Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci USA 1997, 94:14306-14313.
11. Daniels P.S., Jeffries S., Yates P., Schild G.C., Rogers G.N., Paulson J.C., et al. The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. EMBO J 1987, 6:1459-1465.
12. Ruigrok R.W., Martin S.R., Wharton S.A., Skehel J.J., Bayley P.M., Wiley D.C. Conformational changes in the hemagglutinin of influenza virus which accompany heat-induced fusion of virus with liposomes. Virology 1986, 155:484-497.
13. Clinical Trials. In: Health, N.I.o. editors; 2010.
14. Bodian D.L., Yamasaki R.B., Buswell R.L., Stearns J.F., White J.M., Kuntz I.D. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 1993, 32:2967-2978.
15. Luo G., Torri A., Harte W.E., Danetz S., Cianci C., Tiley L., et al. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol 1997, 71:4062-4070.
16. Maddry J.A., Chen X., Jonsson C.B., Ananthan S., Hobrath J., Smee D.F., et al. Discovery of novel benzoquinazolinones and thiazoloimidazoles, inhibitors of influenza H5N1 and H1N1 viruses, from a cell-based high-throughput screen. J Biomol Screen 2011, 16:73-81.
17. Plotch S.J., O'Hara B., Morin J., Palant O., LaRocque J., Bloom J.D., et al. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol 1999, 73:140-151.
18. Russell R.J., Kerry P.S., Stevens D.J., Steinhauer D.A., Martin S.R., Gamblin S.J., et al. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA 2008, 105:17736-17741.
19. Staschke K.A., Hatch S.D., Tang J.C., Hornback W.J., Munroe J.E., Colacino J.M., et al. Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid. Virology 1998, 248:264-274.
20. Wagner R.R. Studies on the inactivation of influenza virus; comparison of the effects of p-benzoquinone and various inorganic oxidizing agents. Yale J Biol Med 1951, 23:288-298.
21. Nobusawa E., Aoyama T., Kato H., Suzuki Y., Tateno Y., Nakajima K. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 1991, 182:475-485.
22. Wood J.M., Mumford J., Schild G.C., Webster R.G., Nicholson K.G. Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals. Dev Biol Stand 1986, 64:169-177.
23. Ihaka, R.G.a.R. R-project. 1997.
24. Faraway J.J. Linear Models with R 2004, Chapman & Hall/CRC, Boca Raton, FL.
25. Faraway J.J. Extending Linear Models with R: Generalized Linear, Mixed Effects and Nonparametric Regression Models 2006, Chapman & Hall/CRC, Boca Raton FL.
26. Luykx D.M., Casteleijn M.G., Jiskoot W., Westdijk J., Jongen P.M. Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur J Pharm Sci 2004, 23:65-75.
27. Coenen F., Tolboom J.T., Frijlink H.W. Stability of influenza sub-unit vaccine. Does a couple of days outside the refrigerator matter?. Vaccine 2006, 24:525-531.
28. Nakowitsch S., Wolschek M., Morokutti A., Ruthsatz T., Krenn B.M., Ferko B., et al. Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. Vaccine 2011, 29:3517-3524.
29. Weldon W.C., Wang B.Z., Martin M.P., Koutsonanos D.G., Skountzou I., Compans R.W. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 2010, 5.
30. Bommakanti G., Citron M.P., Hepler R.W., Callahan C., Heidecker G.J., Najar T.A., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 2010, 107:13701-13706.
31. Quan F.S., Li Z.N., Kim M.C., Yang D., Compans R.W., Steinhauer D.A., et al. Immunogenicity of low-pH treated whole viral influenza vaccine. Virology 2011, 417:196-202.
32. Steven Rockman P.S.M.G. Development and testing of the Australian pandemic influenza vaccine - a timely response. Microbiology Australia 2011, 32:10-14.